CFTR and cystic fibrosis: The first study of CRISPR/Cas9 as a potential therapy for CF used site-specific knock-in of the correct CFTR sequence to robustly restore CFTR function in human intestinal stem cell organoids derived from patients homozygous for the Phe508del mutation (Schwank et al., 2013).